Search

Your search keyword '"Isaac Kriley"' showing total 12 results
Start Over Author "Isaac Kriley" Publisher american association for cancer research (aacr)
12 results on '"Isaac Kriley"'

2. Supplementary Tables 1 and 2 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Author

Steven A. Rosenberg, David S. Schrump, Isaac Kriley, Biman C. Paria, Scott Kivitz, Satyajit Ray, Todd Prickett, Thomas E. Shelton, Parisa Malekzadeh, Drew Deniger, Anna Pasetto, Jared J. Gartner, Li Jia, Yong-Chen Lu, Eric Tran, Paul F. Robbins, Maria Parkhurst, and Winifred Lo

Abstract

Supplementary Tables 1 and 2

Published
2023
Full Text
View/download PDF

4. Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Author

Steven A. Rosenberg, David S. Schrump, Isaac Kriley, Biman C. Paria, Scott Kivitz, Satyajit Ray, Todd Prickett, Thomas E. Shelton, Parisa Malekzadeh, Drew Deniger, Anna Pasetto, Jared J. Gartner, Li Jia, Yong-Chen Lu, Eric Tran, Paul F. Robbins, Maria Parkhurst, and Winifred Lo

Abstract

Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we report the identification and characterization in one patient of T-cell receptors (TCRs) recognizing mutated p53 p.R175H, which is shared among a subset of patients with cancer. Tumor-infiltrating lymphocytes were screened for recognition of mutated neoantigens in a patient with metastatic colorectal cancer. HLA-A*0201–restricted recognition of mutated p53 p.R175H was identified, and the minimal peptide epitope was HMTEVVRHC. Reactive T cells were isolated by tetramer sorting, and three TCRs were identified. These TCRs mediated recognition of commercially available ovarian cancer, uterine carcinoma, and myeloma cell lines, as well as an NIH patient–derived esophageal adenocarcinoma line that endogenously expressed p53 p.R175H and HLA-A*0201. They also mediated recognition of p53 p.R175H+ colon, breast, and leukemia cell lines after transduction with a retrovirus encoding HLA-A*0201. This work demonstrates that common shared mutated epitopes such as those found in p53 can elicit immunogenic responses and that the application of ACT may be extended to patients with any cancer histology that expresses both HLA-A*0201 and the p53 p.R175H mutation.

Published
2023
Full Text
View/download PDF

5. Supplementary Figures from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Author

Steven A. Rosenberg, David S. Schrump, Isaac Kriley, Biman C. Paria, Scott Kivitz, Satyajit Ray, Todd Prickett, Thomas E. Shelton, Parisa Malekzadeh, Drew Deniger, Anna Pasetto, Jared J. Gartner, Li Jia, Yong-Chen Lu, Eric Tran, Paul F. Robbins, Maria Parkhurst, and Winifred Lo

Abstract

Supplementary Figures 1, 2, 3, 4, 6 and 7

Published
2023
Full Text
View/download PDF

6. Supplemental Table 2 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

Phenotypic characterization of TIL.

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 2 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

HLA typing data.

Published
2023
Full Text
View/download PDF

8. Supplemental Table 1 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

Tumor mutation profile.

Published
2023
Full Text
View/download PDF

9. Supplemental Table 3 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

Mutation expression in metastatic lesions at autopsy.

Published
2023
Full Text
View/download PDF

10. Supplemental Figure 3 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

Clonal architecture of 4062 tumor.

Published
2023
Full Text
View/download PDF

11. Supplemental Figure 1 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

Recognition of mRNA-encoded RBPJ mutation.

Published
2023
Full Text
View/download PDF

12. Data from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

Author

Steven A. Feldman, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins, Yong-Chen Lu, Zhili Zheng, John R. Wunderlich, Lily Lu, Isaac Kriley, Harshini Chinnasamy, Li Jia, Mary A. Black, Hui Xu, Robert P.T. Somerville, Jared J. Gartner, Todd D. Prickett, Jessica S. Crystal, Nikolaos Zacharakis, and Yasmine Assadipour

Abstract

Purpose: The administration of autologous tumor-infiltrating lymphocytes (TILs) can mediate durable tumor regressions in patients with melanoma likely based on the recognition of immunogenic somatic mutations expressed by the cancer. There are limited data regarding the immunogenicity of mutations in breast cancer. We sought to identify immunogenic nonsynonymous mutations in a patient with triple-negative breast cancer (TNBC) to identify and isolate mutation-reactive TILs for possible use in adoptive cell transfer.Experimental Design: A TNBC metastasis was resected for TIL generation and whole-exome sequencing. Tandem minigenes or long 25-mer peptides encoding selected mutations were electroporated or pulsed onto autologous antigen-presenting cells, and reactivity of TIL was screened by upregulation of CD137 and IFNγ ELISPOT. The nature of the T-cell response against a unique nonsynonymous mutation was characterized.Results: We identified 72 nonsynonymous mutations from the tumor of a patient with TNBC. CD4+ and HLA-DRB1*1501–restricted TILs isolated from this tumor recognized a single mutation in RBPJ (recombination signal binding protein for immunoglobulin kappa J region). Analysis of 16 metastatic sites revealed that the mutation was ubiquitously present in all samples.Conclusions: Breast cancers can express naturally processed and presented unique nonsynonymous mutations that are recognized by a patient's immune system. TILs recognizing these immunogenic mutations can be isolated from a patient's tumor, suggesting that adoptive cell transfer of mutation-reactive TILs could be a viable treatment option for patients with breast cancer. Clin Cancer Res; 23(15); 4347–53. ©2017 AACR.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results